Terms: = Germ cell tumor AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Treatment
104 results:
1. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
Stassen RC; Maas CCHM; van der Veldt AAM; Lo SN; Saw RPM; Varey AHR; Scolyer RA; Long GV; Thompson JF; Rutkowski P; Keilholz U; van Akkooi ACJ; Verhoef C; van Klaveren D; Grünhagen DJ
Lancet Oncol; 2024 Apr; 25(4):509-517. PubMed ID: 38547894
[TBL] [Abstract] [Full Text] [Related]
2. A combined opposite targeting of p110δ PI3K and rhoa abrogates skin cancer.
Tzenaki N; Xenou L; Goulielmaki E; Tsapara A; Voudouri I; Antoniou A; Valianatos G; Tzardi M; De Bree E; Berdiaki A; Makrigiannakis A; Papakonstanti EA
Commun Biol; 2024 Jan; 7(1):26. PubMed ID: 38182748
[TBL] [Abstract] [Full Text] [Related]
3. Elucidation of GPR55-Associated Signaling behind THC and LPI Reducing Effects on Ki67-Immunoreactive Nuclei in Patient-Derived Glioblastoma cells.
Kolbe MR; Hohmann T; Hohmann U; Maronde E; Golbik R; Prell J; Illert J; Strauss C; Dehghani F
Cells; 2023 Nov; 12(22):. PubMed ID: 37998380
[TBL] [Abstract] [Full Text] [Related]
4. Identification of hub gene and lncRNA signature related to entotic cell death in cutaneous melanoma for prognostic and immune prediction.
Zhang C; Shen C
Medicine (Baltimore); 2023 Nov; 102(45):e35881. PubMed ID: 37960805
[TBL] [Abstract] [Full Text] [Related]
5. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
[TBL] [Abstract] [Full Text] [Related]
6. Identification of immune-related hub genes and construction of an immune-related gene prognostic index for low-grade glioma.
Zhou J; Guo H; Liu L; Jin Z; Zhang W; Tang T
J Cell Mol Med; 2023 Dec; 27(23):3851-3863. PubMed ID: 37775993
[TBL] [Abstract] [Full Text] [Related]
7. Scoparone attenuates glioma progression and improves the toxicity of temozolomide by suppressing rhoa/ROCK1 signaling.
Zhou Y; Han Z; Zhao Z; Zhang J
Environ Toxicol; 2024 Feb; 39(2):562-571. PubMed ID: 37449671
[TBL] [Abstract] [Full Text] [Related]
8. A Syx-rhoa-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma.
Lin WH; Feathers RW; Cooper LM; Lewis-Tuffin LJ; Chen J; Sarkaria JN; Anastasiadis PZ
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427593
[TBL] [Abstract] [Full Text] [Related]
9. Factors affecting eye conservation and metastasis in posterior uveal melanomas.
Nalcı Baytaroğlu H; Gündüz AK; Mirzayev I; Özalp Ateş FS
Eur J Ophthalmol; 2023 Sep; 33(5):2024-2033. PubMed ID: 36762394
[TBL] [Abstract] [Full Text] [Related]
10. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract] [Full Text] [Related]
11. Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Yagi C; Tatsuoka J; Sano E; Hanashima Y; Ozawa Y; Yoshimura S; Yamamuro S; Sumi K; Hara H; Katayama Y; Yoshino A
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36281939
[TBL] [Abstract] [Full Text] [Related]
12. Monensin synergizes with chemotherapy in uveal melanoma through suppressing rhoa.
Zeng C; Long M; Lu Y
Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):35-42. PubMed ID: 36043455
[TBL] [Abstract] [Full Text] [Related]
13. Paradoxical role of β8 integrin on angiogenesis and vasculogenic mimicry in glioblastoma.
Liu Y; Xu X; Zhang Y; Mo Y; Sun X; Shu L; Ke Y
Cell Death Dis; 2022 Jun; 13(6):536. PubMed ID: 35676251
[TBL] [Abstract] [Full Text] [Related]
14. PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor.
Wang K; Pan S; Zhao P; Liu L; Chen Z; Bao H; Wang H; Zhang Y; Zhuge Q; Yang J
Theranostics; 2022; 12(8):3847-3861. PubMed ID: 35664063
[No Abstract] [Full Text] [Related]
15. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ; Rutkowski P; Queirolo P; Del Vecchio M; Mackiewicz J; Chiarion-Sileni V; de la Cruz Merino L; Khattak MA; Schadendorf D; Long GV; Ascierto PA; Mandala M; De Galitiis F; Haydon A; Dummer R; Grob JJ; Robert C; Carlino MS; Mohr P; Poklepovic A; Sondak VK; Scolyer RA; Kirkwood JM; Chen K; Diede SJ; Ahsan S; Ibrahim N; Eggermont AMM;
Lancet; 2022 Apr; 399(10336):1718-1729. PubMed ID: 35367007
[TBL] [Abstract] [Full Text] [Related]
16. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
[TBL] [Abstract] [Full Text] [Related]
17. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors.
Tawfik B; Ray D; Moynihan M; Princic N
J Med Econ; 2021; 24(1):1337-1345. PubMed ID: 34763589
[TBL] [Abstract] [Full Text] [Related]
18. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
[TBL] [Abstract] [Full Text] [Related]
19. Glioblastoma invasion factor ODZ1 is induced by microenvironmental signals through activation of a Stat3-dependent transcriptional pathway.
Vidal V; Gutierrez O; Talamillo A; Velasquez C; Fernandez-Luna JL
Sci Rep; 2021 Aug; 11(1):16196. PubMed ID: 34376733
[TBL] [Abstract] [Full Text] [Related]
20. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract] [Full Text] [Related]
[Next]
